Eosinophilic esophagitis

Management and pharmacotherapy

Paola De Angelis, G. Morino, A. Pane, F. Torroni, P. Francalanci, T. Sabbi, F. Foschia, T. Caldaro, G. Federici di Abriola, L. Dall'Oglio

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Eosinophilic esophagitis represents the most debated disease of the last 10 years, too often speculated or overestimated and certainly well known and examined. The aim of this study was to summarize the recent therapeutic trends in order to show persistent doubts regarding several debated therapies. The study combined the most recent international literature and the authors' daily experience to define the scope of the review, with limits caused by a lack of available randomized studies between dietetic and pharmacological treatment. It was concluded that eosinophilic esophagitis is an immunoallergic disease that is generally caused by identifiable food and environmental allergens although, in a minority of cases, the etiological trigger remains undetermined. Therapy usually fights the responsible agents, but sometimes they are not resolved. A need for more pathogenetically driven treatments is invoked.

Original languageEnglish
Pages (from-to)731-740
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number5
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Eosinophilic Esophagitis
Drug Therapy
Therapeutics
Dietetics
Allergens
Pharmacology
Food

Keywords

  • Elemental diet
  • Eosinophilic esophagitis
  • Fluticasone propionate
  • Mepolizumab
  • Methylprednisolone
  • Montelukast
  • Prednisone
  • Restricted diet

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Eosinophilic esophagitis : Management and pharmacotherapy. / De Angelis, Paola; Morino, G.; Pane, A.; Torroni, F.; Francalanci, P.; Sabbi, T.; Foschia, F.; Caldaro, T.; Federici di Abriola, G.; Dall'Oglio, L.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 5, 04.2008, p. 731-740.

Research output: Contribution to journalArticle

@article{752262021a094f029806f4f2eeca7c39,
title = "Eosinophilic esophagitis: Management and pharmacotherapy",
abstract = "Eosinophilic esophagitis represents the most debated disease of the last 10 years, too often speculated or overestimated and certainly well known and examined. The aim of this study was to summarize the recent therapeutic trends in order to show persistent doubts regarding several debated therapies. The study combined the most recent international literature and the authors' daily experience to define the scope of the review, with limits caused by a lack of available randomized studies between dietetic and pharmacological treatment. It was concluded that eosinophilic esophagitis is an immunoallergic disease that is generally caused by identifiable food and environmental allergens although, in a minority of cases, the etiological trigger remains undetermined. Therapy usually fights the responsible agents, but sometimes they are not resolved. A need for more pathogenetically driven treatments is invoked.",
keywords = "Elemental diet, Eosinophilic esophagitis, Fluticasone propionate, Mepolizumab, Methylprednisolone, Montelukast, Prednisone, Restricted diet",
author = "{De Angelis}, Paola and G. Morino and A. Pane and F. Torroni and P. Francalanci and T. Sabbi and F. Foschia and T. Caldaro and {Federici di Abriola}, G. and L. Dall'Oglio",
year = "2008",
month = "4",
doi = "10.1517/14656566.9.5.731",
language = "English",
volume = "9",
pages = "731--740",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Eosinophilic esophagitis

T2 - Management and pharmacotherapy

AU - De Angelis, Paola

AU - Morino, G.

AU - Pane, A.

AU - Torroni, F.

AU - Francalanci, P.

AU - Sabbi, T.

AU - Foschia, F.

AU - Caldaro, T.

AU - Federici di Abriola, G.

AU - Dall'Oglio, L.

PY - 2008/4

Y1 - 2008/4

N2 - Eosinophilic esophagitis represents the most debated disease of the last 10 years, too often speculated or overestimated and certainly well known and examined. The aim of this study was to summarize the recent therapeutic trends in order to show persistent doubts regarding several debated therapies. The study combined the most recent international literature and the authors' daily experience to define the scope of the review, with limits caused by a lack of available randomized studies between dietetic and pharmacological treatment. It was concluded that eosinophilic esophagitis is an immunoallergic disease that is generally caused by identifiable food and environmental allergens although, in a minority of cases, the etiological trigger remains undetermined. Therapy usually fights the responsible agents, but sometimes they are not resolved. A need for more pathogenetically driven treatments is invoked.

AB - Eosinophilic esophagitis represents the most debated disease of the last 10 years, too often speculated or overestimated and certainly well known and examined. The aim of this study was to summarize the recent therapeutic trends in order to show persistent doubts regarding several debated therapies. The study combined the most recent international literature and the authors' daily experience to define the scope of the review, with limits caused by a lack of available randomized studies between dietetic and pharmacological treatment. It was concluded that eosinophilic esophagitis is an immunoallergic disease that is generally caused by identifiable food and environmental allergens although, in a minority of cases, the etiological trigger remains undetermined. Therapy usually fights the responsible agents, but sometimes they are not resolved. A need for more pathogenetically driven treatments is invoked.

KW - Elemental diet

KW - Eosinophilic esophagitis

KW - Fluticasone propionate

KW - Mepolizumab

KW - Methylprednisolone

KW - Montelukast

KW - Prednisone

KW - Restricted diet

UR - http://www.scopus.com/inward/record.url?scp=41949132491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949132491&partnerID=8YFLogxK

U2 - 10.1517/14656566.9.5.731

DO - 10.1517/14656566.9.5.731

M3 - Article

VL - 9

SP - 731

EP - 740

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -